VTE is preventable

Acutely ill medical patients are at risk

Acutely ill medical patients

A vulnerable population with limited options

Shared risk factors1

Immobility, hypercoagulability, and inflammation are shared risk factors for various types of acutely ill medical patients.
VTE Webnar

Register for the webinar*
Venous Thromboembolism: Pervasive, Persistent, Preventable

First in a series of live peer-to-peer webinars about the unmet need for VTE prophylaxis in acutely ill medical patients after hospital discharge.

*For US health care professionals only.

See the full scope of this deadly
yet preventable problem2,3

7.7 million hospitalized acutely ill medical patients are at risk of VTE in the US each year4

Additional risk factors for VTE among acutely ill medical patients include
age ≥75 years, reduced mobility, elevated D-dimer, renal impairment, and prior cancer.5-8

Patient risk factors for VTE
8 x greater risk of VTE in hospitalized medical patients vs the general population

greater risk of VTE in hospitalized medical patients versus the general population9

Khan et al, 2012

Most hospitalized patients are acutely ill medical patients10

Nearly half of these patients are at risk of VTE events10

55%

ACUTELY ILL MEDICAL PATIENTS

45%

SURGICAL PATIENTS

VTE Newsletter Signup

Register for updates*

Concerned about your acutely ill medical patients and VTE?
Sign up to receive updates and access to new resources as they become available.

*For US health care professionals only.

References
  1. DiNisio M, Porreca E. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux. Drug Des Devel Ther. 2013;7:973-980.
  2. Futterman LG, Lemberg L. A silent killer—often preventable. Am J Crit Care. 2004;13(5):431-436.
  3. Korjian S, Daaboul Y, Halaby R, et al. Extended-duration thromboprophylaxis among acute medically ill patients: an unmet need. J Cardiovasc Pharmacol Ther. 2016;21(3):227-232.
  4. Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777-782.
  5. Cohen AT, Spiro TE, Büller HR, et al; the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523.
  6. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; the ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-2177.
  7. Hull RD, Schellong SM, Tapson VF, et al. Extended duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Int Med. 2010;153(1):8-18.
  8. Cohen AT, Harrington RA, Goldhaber SZ, et al; the APEX Investigtors. Extended Thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534-544.
  9. Khan SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e195S-e226S.
  10. Cohen AT, Tapson VF, Bergmann J-F, et al; the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.

Worried about VTE risk?  Learn About A Treatment Option

Okay Okay Okay Okay Okay  Cancel